GLP 1 and obesity stocks
Heavily traded in GLP 1 and obesity
Turnover over $10M/day9 of about 30 companies in this theme turn over more than $10M in a typical session. Largest market value first. Data as of Oct 30, 2026.
| Company | Turnover | 1Y return | Next report |
|---|---|---|---|
| LLYEli Lilly and Company | $3.09B | +69.68% | — |
| NVONovo Nordisk A/S | $405.39M | −21.01% | Reports Nov 4, 2026 |
| MDGLMadrigal Pharmaceuticals, Inc. | $112.65M | +2.40% | Reports Nov 3, 2026 |
| 128940.KSHanmi Pharm. Co., Ltd. | $36.28B | −5.03% | — |
| VKTXViking Therapeutics, Inc. | $78.77M | −23.74% | — |
| MBXMBX Biosciences, Inc. | $25.29M | +179.41% | Reports Nov 5, 2026 |
| 008930.KSHanmi Science Co., Ltd. | $10.22B | +9.36% | — |
| KLRAKailera Therapeutics, Inc. | $15.03M | −48.42% | Reports Nov 4, 2026 |
Turnover is the median value traded in one session, measured over the past 50 sessions. It describes trading activity in a stock and nothing about the company behind it.
Table
31 companies, largest market value first.
Data as of Oct 30, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | $1.22T | Mega cap | +69.68% |
| NVO | Novo Nordisk A/S | $172.63B | Large cap | −21.01% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $9.97B | Mid cap | +2.40% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $3.68B | Mid cap | −5.03% |
| VKTX | Viking Therapeutics, Inc. | $3.42B | Mid cap | −23.74% |
| MBX | MBX Biosciences, Inc. | $2.63B | Mid cap | +179.41% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.14B | Mid cap | +9.36% |
| KLRA | Kailera Therapeutics, Inc. | $1.74B | Small cap | −48.42% |
| GPCR | Structure Therapeutics Inc. | $1.53B | Small cap | −25.80% |
| IVA | Inventiva S.A. | $881.10M | Small cap | −10.34% |
| LXRX | Lexicon Pharmaceuticals, Inc. | $658.53M | Small cap | +11.28% |
| ENTX | Entera Bio Ltd. | $542.64M | Small cap | +14.29% |
| ALT | Altimmune, Inc. | $416.27M | Small cap | −46.50% |
| WW | WW International, Inc. | $150.48M | Small cap | −56.90% |
| MED | Medifast, Inc. | $137.10M | Small cap | +0.66% |
| VANI | Vivani Medical, Inc. | $102.83M | Small cap | −35.59% |
| RANI | Rani Therapeutics Holdings, Inc. | $86.46M | Micro cap | −63.53% |
| IBIO | iBio, Inc. | $40.42M | Micro cap | −47.17% |
| ALGS | Aligos Therapeutics, Inc. | $31.41M | Micro cap | −41.58% |
| GUTS | Fractyl Health, Inc. | $13.15M | Micro cap | −20.68% |
| ASBP | Aspire Biopharma Holdings, Inc. | $11.89M | Micro cap | −46.19% |
| PTN | Palatin Technologies, Inc. | $9.08M | Micro cap | −16.44% |
| LEXX | Lexaria Bioscience Corp. | $7.94M | Micro cap | +293.12% |
| MTVA | MetaVia Inc. | $7.51M | Micro cap | −89.06% |
| SKYE | Skye Bioscience, Inc. | $6.73M | Micro cap | −17.09% |
| TCRT | Alaunos Therapeutics, Inc. | $6.50M | Micro cap | −30.51% |
| ELAB | PMGC Holdings Inc. | $2.14M | Micro cap | −98.12% |
| ALVAL.PA | Valbiotis SA | — | — | −28.88% |
| IVA.PA | Inventiva S.A. | — | Small cap | −18.65% |
| OPTI.L | OptiBiotix Health Plc | — | — | −37.91% |
| VERU | Veru Inc. | — | — | −36.29% |
Covers ~23,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Price and the 52-week distance are in the currency the stock trades in; only market values are converted.
We cover 31 companies grouped under the GLP 1 and obesity theme. The median market value in the group is $150.48M. Among the 26 with a price from the latest session, the median move over the past trading day is +0.59%. 27% of the 30 with a 200-day average trade above it. Price change over the past year runs from −56.9% to +14.3% across the middle 80 percent of the group, with a median of −23.7%.